8329 — Shenzhen Neptunus Interlong Bio-technique Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Market Cap
HK$241.63m
Enterprise Value
HK$41.68m
Revenue
CNY1.06bn

Annual income statement for Shenzhen Neptunus Interlong Bio-technique Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,081	1,031	839	987	1,065
Cost of Revenue
Gross Profit	631	576	368	444	439
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,001	980	795	897	1,029
Operating Profit	80.2	51	43.7	89.3	36.2
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	78.8	50.2	39.1	82.3	30.7
Provision for Income Taxes
Net Income After Taxes	63.4	38.7	34.3	63.8	14.5
Minority Interest
Net Income Before Extraordinary Items
Net Income	59.7	36.6	36	54.3	24.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	59.7	36.6	36	54.3	24.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.037	0.032	0.021	0.034	0.019